30 closest matches · ranked by relevance
Lymphomas · Solid Tumors · NSCLC
Primary: Phase 2: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer — 0; 0; 0; 1…
Carcinoma, Small Cell · Lung Cancer · Small Cell Lung Cancer
Primary: Proportion of Evaluable Participants Who Experience a Partial Response (PR) or Complete Response (CR) Reported Along With an 80% Confidence Interval. — 0.1; 0; 0.2; 0…
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Adult Rhabdomyosarcoma · Adult Synovial Sarcoma · Childhood Hepatoblastoma
Primary: Disease Response — 10; 10; 19; 10 patient
Recurrent Chronic Lymphocytic Leukemia · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma
Primary: Best Overall Response Rate (ORR) — 2 Participants
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 5 Percentage of participants
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Advanced Malignant Solid Neoplasm · Recurrent Childhood Ependymoma · Recurrent Ewing Sarcoma
Primary: Objective Response Rate — 0 percentage of participants
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Recurrent Lymphoma · Recurrent Malignant Solid Neoplasm · Recurrent Primary Central Nervous System Neoplasm
Primary: MTD/RP2D of Pevonedistat in Combination With Irinotecan and Temozolomide — 35 mg/m^2
Small Cell Carcinoma · Carcinoma, Non-Small-Cell Lung · Neuroendocrine Tumors
Primary: Overall Survival — 6.85; 7.6; 7.5 Months
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control(DC) Rate of Gefitinib Retreatment Per RECIST Criteria (V1.1) and Assessed by CT — 65.2 percentage of participant with DC
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Response Rate — 0 Percentage of patients
Lung Cancer
Primary: The Objective Overall Response — 7; 12; 7; 19 participants
CD19+ Diffuse Large B-cell Lymphomas · Follicular Lymphomas · Mantle Cell Lymphomas
Primary: Dose-limiting Toxicity — 8.33 percentage of subjects
Glioblastoma · Recurrent Glioblastoma · Supratentorial Glioblastoma
Primary: Objective Response Rate (ORR) — 0 participants
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Non-Hodgkin Lymphoma · Ann Arbor Stage IV Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 0 percentage of patients
Brain Tumors · Spinal Cord Tumors
Primary: Time to Progression — 7.8 Months
Small Cell Lung Cancer
Primary: 8-Week Progression-Free Rate — 0.0; 8.3 percentage of participants
Metastatic Melanoma · Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor · Recurrent Hodgkin Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Nivolumab as a Single Agent or in Combination With Ipilimumab — 0; 0; 5; 0 Participants
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
T-Cell Lymphoma Relapsed · T-Cell Lymphoma Refractory
Primary: Best Overall Response Rate During the First 8 Cycles of Treatment — 5 Participants
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Advanced Solid Tumors
Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma · Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 25 percentage of participants
Carcinoma, Small Cell
Primary: Number of Participants With Objective Tumor Response — 0; 0 Participants
Small Cell Lung Cancer · Extra-Pulmonary Small Cell Carcinomas
Primary: Phase II: Clinical Benefit Rate
B Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Primary: Complete Response (CR or CRi) — 0 proportion of participants
Recurrent Malignant Solid Neoplasm · Recurrent Osteosarcoma · Refractory Malignant Solid Neoplasm
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 1 Participants